- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:54 | Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | 62 | GlobeNewswire (Europe) | - Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -... ► Artikel lesen | |
| 12:37 | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12:15 | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12:12 | Zenas BioPharma GAAP EPS of -$1.46 beats by $0.22 | 2 | Seeking Alpha | ||
| 12:06 | Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 183 | GlobeNewswire (Europe) | - Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - - Obexelimab... ► Artikel lesen | |
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 30.04. | Zenas BioPharma rises as CEO continues insider purchases | 1 | Seeking Alpha | ||
| 17.04. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 31.03. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | 4 | Seeking Alpha | ||
| 27.03. | Zenas BioPharma prices $200M convertible notes, $100M stock sale | 3 | Investing.com | ||
| 27.03. | Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million | 1 | GlobeNewswire (USA) | ||
| 26.03. | Zenas BioPharma launches convertible notes, stock offerings | 1 | Investing.com | ||
| 26.03. | Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock | 1 | Seeking Alpha | ||
| 26.03. | Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock | 3 | GlobeNewswire (USA) | ||
| 16.03. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 16.03. | Guggenheim raises Zenas Biopharma stock price target to $55 on pipeline progress | 2 | Investing.com | ||
| 16.03. | Guggenheim hebt Kursziel für Zenas Biopharma nach Pipeline-Fortschritten auf 55 US-Dollar an | 2 | Investing.com Deutsch | ||
| 16.03. | Morgan Stanley hebt Kursziel für Zenas Biopharma wegen IgG4-RD-Aussichten an | 6 | Investing.com Deutsch | ||
| 16.03. | Morgan Stanley raises Zenas Biopharma stock price target on IgG4-RD outlook | 1 | Investing.com | ||
| 16.03. | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 286,45 | 0,00 % | Maria Elvira Salazar trades in Amgen, Carrier Global, and Microsoft stocks | ||
| REGENERON PHARMACEUTICALS | 612,60 | -0,57 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| BIOMARIN PHARMACEUTICAL | 45,650 | +1,35 % | BioMarin stock price target raised to $110 by Freedom Broker | ||
| ARROWHEAD PHARMACEUTICALS | 66,84 | -0,74 % | Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026 | ||
| INSMED | 102,54 | +3,79 % | Insmed Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Insmed (INSM) reported a first quarter net loss of $163.6 million, or $0.76 per share, compared to a net loss of $256.6 million, or $1.42 per share, a year ago. Product... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 40,320 | -0,25 % | SWEDISH ORPHAN BIOVITRUM AB: Bulletin from Sobi's Annual General Meeting (AGM) | ||
| SCHOLAR ROCK | 40,560 | -3,20 % | Scholar Rock anticipates apitegromab approval by September 30 as FDA accepts SMA BLA with two fill-finish sites | ||
| CRINETICS PHARMACEUTICALS | 30,960 | -0,90 % | Crinetics Pharma übertrifft Umsatzprognose für Q1 2026 - Aktie dennoch unter Druck | ||
| PROQR THERAPEUTICS | 1,338 | -0,22 % | ProQR Therapeutics N.V. - 6-K, Report of foreign issuer | ||
| ENSYSCE BIOSCIENCES | 0,325 | +2,69 % | Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR Overdose Protection Technology | ~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 59,50 | +0,03 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| TEVOGEN BIO | 7,000 | +0,43 % | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| EVOTEC | 4,490 | -11,61 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | +0,35 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +1,17 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 19,150 Euro und damit -0,05 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.